Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3796-3802

  Chang, Yoon Soo ^a   Gong, Koo ^b   Sun, Shihua ^a   Liu, Diane ^a   El Naggar, Adel K ^a   Khuri, Fadlo R ^a   Hong, Waun Ki ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 0036899977     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ginsberg, R. J., Vokes, E. E., and Raben. A. Non-small cell lung cancer. In: V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg, (eds), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 858-911, Philadelphia-New York: Lippincott-Raven. 1997.
2. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. (Bethesda), 91: 151-156, 1999.
3. Macauly, V. M. Insulin-like growth factors and cancer. Br. J. Cancer, 65: 311-320, 1992.
4. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev., 16: 33-34, 1995.
5. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. Insulin-like growth factor I(IGF-1) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 2687-2693, 1997.
6. Prager, D., Li, H. L., Asa, S., and Melmed, S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. Natl. Acad. Sci. USA, 91: 2181-2185, 1994.
7. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T., Jr. Molecular and cellular aspects of insulin-like growth factor I receptor. Endocr. Rev., 16: 143-163, 1995.
8. Pollak, M., Beamer, W., and Zhang, J. C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev., 17: 383-390, 1999.
9. Hwa, V., Oh, Y., and Rosenfeld, R. G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev., 20: 761-787, 1999.
10. Jaques, G., Noll, K., Wegmann, B., Witten, S., Kogan, E., Radulescu, R. T., and Havemann, K. Nucleir localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology, 138: 1767-1770, 1997.
11. Strom, S. S., Wu, S., Sigurdson, A. J., Hsu, T. C., Fueger, J. J., Lopez, J., Tee, P. G., and Spitz. M. R. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J. Natl. Cancer Inst. Monogr., 18: 29-33, 1995.
12. Rajah, R., Valentinis, B., and Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53-and IGF-independent mechanism. J. Cell Biol., 272: 12181-12188, 1997.
13. Oh, Y., Muller, H. L., Ng, L., and Rosenfeld, R. Transforming growth factor-β induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem., 270: 13589-13592, 1995.
14. 3 and its analog EB1089. Int. J. Oncol., 13: 137-143, 1998.
15. Gucev, Z. S., Oh, Y., Kelley, K. M., and Rosenfeld, R. G. Insulin-like growth factor binding protein-3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res., 56: 1545-1550, 1996.
16. Huynh, H., Nickerson, T., Pollak, M., and Yang, X. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI182780. Clin. Cancer Res., 2: 2037-2042, 1996.
17. Nickerson, T., and Pollak, M. Bicalutamide [Casodex]-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology, 54: 1120-1125, 1999.
18. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature (Lond.), 377: 646-648, 1995.
19. Rozen, F., Zhang, J., and Pollak, M. Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J. Oncol., 13: 865-869, 1998.
20. Walker, G. E., Wilson, E. M., Powell, D., and Oh, Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves a Sp1/Sp3 multiprotein complex. Endocrinology, 142: 3817-3827, 2001.
21. Cohen, P., Graves, H. C., Peehl, D. M., Kamarei, M., Guidice, L. C., and Rosenfeld, R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab., 75: 1046-1053, 1992.
22. Conover, C. A., and De Leon, D. D. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of Cathepsin D. J. Biol. Chem., 269: 7076 -7080, 1994.
23. Favoni, R. E., de Cupis, A., Ravera, F., Cantoni, C., Pirani, P., Ardizzoni, A., Noonan, D., and Biassoni, R. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int. J. Cancer, 56: 858-866, 1994.
24. Quinn, K. A., Treston, A. M., Unsworth, E. J., Miller, M. J., Vos, M., Grimley, C., Battey, J., Mulshine, J. L., and Cuttitta, F. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem., 271: 11477-11483, 1996.
25. Noll, K., Wegmann, B. R., Havemann, K., and Jaques, G. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in non-small cell lung cancer cell lines. J. Clin. Endocrinol. Metab., 81: 2653-2662, 1996.
26. Mountain, C. F. Value of the new TNM staging system for lung cancer. Chest, 96 (Suppl.): 47S-49S, 1997.
27. Furstenberger, G., and Senn, H. J. Insulin-like growth factors and cancer. Lancet Oncology, 3:298-302, 2002.
28. Lee, H-Y., Chun, K-H., Liu, B., Wiehle, S. A., Cristiano, R. J., Hong, W. K., Cohen, P., and Kurie, J. M. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res., 62: 3530-3537, 2002.
29. Chang, Y. S., Wang, L., Liu, D., Mao, L., Hong, W. K., Khuri, F. R., and Lee, H-Y. Correlation between IGFBP-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin. Cancer Res. 8: 3669-3675, 2002
30. Tate, P. H., and Bird, A. P. Effects of NDA methylation on DNA-binding proteins and gene expression. Curr. Opin Genet. Dev., 3: 226-231, 1993.
31. Del Giudice, M. E., Fantus, I. G., Ezzat, S., McKeown-Eyssen, G., Page, D., and Goodwin, P. J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat., 47: 111-120, 1998.
32. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H. O., and Trichopoulos, D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J. Natl. Cancer Inst. (Bethesda), 90: 911-915, 1998.
33. Firth, S. M., Fanayan, S., Benn, D., and Baxter, R. C. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem. Biophys. Res. Commun., 246: 325-329, 1998.
34. Collett-Solberg, P. F., and Cohen, P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol. Metab. Clin. North Am., 25: 591-614, 1996.
35. McCusker, R. H., Busby, W. H., Dehoff, M. H., Camacho-Hubner, C., and Clemmons, D. R. Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF-binding proteins. Endocrinology, 129: 939-949, 1991.
36. Claussen, M., Kubler, B., Wendland, M., Neifer, K., Schmidt, B., Zapf, J., and Braulke, T. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by Cathepsin D. Endocrinology, 138: 3797-3803, 1997.
37. Marinaro, J. A., Hendrich, E. C., Leeding, K. S., and Bach, L. A. HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6. Am. J. Physiol. Endocrinol. Metab., 276: E536-42, 1999.
38. Fowlkes, J. L., Enghild, J. J., Suzuki, K., and Nagase, H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem., 269: 25742-25746, 1994.
39. Kubler, B., Cowell, S., Zapf, J., and Braulke, T. Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum. Endocrinology, 139: 1556-1563, 1998.
40. Manes, S., Llorente, M., Lacalle, R. A., Gomez-Mouton, C., Kremer, L., Mira, E., and Martinez, A. C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem., 274: 6935-6945, 1999.
41. Lalou, C., Silve, C., Rosato, R., Segovia, B., and Binoux, M. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology, 135: 2318-2326, 1994.
42. Angelloz-Nicoud, P., and Binoux, M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology, 136: 5485-5492, 1995.